PREVIEW: Abbott Laboratories (ABT) earnings due 26/Jan at 12:30GMT/07:30EST
SourceNewsquawk
SectionUS Equities
Abbott Laboratories (ABT) Q4 2021 (USD): EPS (exp. 1.21/0.89 GAAP), Revenue (exp. 10.71bln)
REVENUE SEGMENTS:
- Diagnostics: (exp. 3.46bln)
- Established Pharmaceuticals: (exp. 1.25bln)
- Medical Devices: (exp. 3.77bln)
- Nutrition: (exp. 2.08bln)
DIVIDEND:
- Qtrly Dividend: (exp. 0.43)
- FY Dividend: (exp. 1.71)
EPS GUIDANCE:
- Q1 2021 EPS View: (exp. 1.13/0.77 GAAP)
- FY 2021 EPS View: (exp. 5.09/3.66 GAAP)
REVENUE GUIDANCE:
- Q1 2021 Revenue View: (exp. 9.82bln)
- FY 2021 Revenue View: (exp. 42.29bln)
- FY 2022 Revenue View: (exp. 40.41bln)
INDEX WEIGHT:
- 0.6% SPX weight
- Sector/Industry: Health Care/Health Care Equipment & Supplies
BROKER RATING:
- Avg Rating: 'Buy'
- Avg Price Target: USD 145.18
- Price Target Changes (last 30 days): 5 upward vs 0 downward